Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 11,000 shares, a growth of 32.5% from the January 31st total of 8,300 shares. Based on an average daily trading volume, of 17,500 shares, the short-interest ratio is presently 0.6 days.

Santen Pharmaceutical Stock Down 0.1 %

Shares of SNPHY traded down $0.01 during midday trading on Tuesday, reaching $9.25. 8,565 shares of the stock were exchanged, compared to its average volume of 12,859. The stock’s 50 day simple moving average is $9.78 and its 200 day simple moving average is $11.02. Santen Pharmaceutical has a twelve month low of $8.65 and a twelve month high of $13.00.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.